Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Michael

Showing results (1011-1020 of 1,111) with videos related to

Pageof 112
Sort By:
Plos One|January 26, 2013
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialSusan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, et al.
Military Medicine|July 11, 2020
Hepatitis B seroprevalence in the U.S. military and its impact on potential screening strategiesPaul T Scott, Robert L Cohen, David M Brett-Major, et al.
Nature|November 15, 2016
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeysErica N Borducchi, Crystal Cabral, Kathryn E Stephenson, et al.
Plos Pathogens|February 7, 2020
Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and ThailandMorgane Rolland, Sodsai Tovanabutra, Bethany Dearlove, et al.
Nature|July 22, 2014
Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeysJames B Whitney, Alison L Hill, Srisowmya Sanisetty, et al.
Journal of Virology|January 12, 2018
HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and PhagocytosisSaintedym Wills, Kwan-Ki Hwang, Pinghuang Liu, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
Cancer|January 5, 2022
TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial resultsDaniela Wittmann, Akanksha Mehta, Sharon L Bober, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
NPJ Vaccines|March 19, 2023
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodiesShikha Shrivastava, Joshua M Carmen, Zhongyan Lu, et al.
Pageof 112

Showing results (1011-1020 of 1,111) with videos related to

Sort By:
Pageof 112
Plos One|January 26, 2013
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialSusan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, et al.
Military Medicine|July 11, 2020
Hepatitis B seroprevalence in the U.S. military and its impact on potential screening strategiesPaul T Scott, Robert L Cohen, David M Brett-Major, et al.
Nature|November 15, 2016
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeysErica N Borducchi, Crystal Cabral, Kathryn E Stephenson, et al.
Plos Pathogens|February 7, 2020
Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and ThailandMorgane Rolland, Sodsai Tovanabutra, Bethany Dearlove, et al.
Nature|July 22, 2014
Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeysJames B Whitney, Alison L Hill, Srisowmya Sanisetty, et al.
Journal of Virology|January 12, 2018
HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and PhagocytosisSaintedym Wills, Kwan-Ki Hwang, Pinghuang Liu, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
Cancer|January 5, 2022
TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial resultsDaniela Wittmann, Akanksha Mehta, Sharon L Bober, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
NPJ Vaccines|March 19, 2023
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodiesShikha Shrivastava, Joshua M Carmen, Zhongyan Lu, et al.
Pageof 112